| Characteristics | Mannitol | Control | All |
| Subjects | 177 | 118 | 295 |
| Age yrs | 23.1±11.66 | 22.8±10.75 | 23.0±11.29 |
| 6–11 | 31 (17.5) | 17 (14.4) | 48 (16.3) |
| 12–17 | 32 (18.1) | 25 (21.1) | 57 (19.3) |
| ≥18 | 114 (64.4) | 76 (64.4) | 190 (64.4) |
| Subjects with diagnosis at age ≤1 yr | 130 (73.4) | 94 (80.0) | 224 (75.9) |
| Caucasian race | 169 (95.5) | 115 (97.5) | 284 (96.3) |
| BMI kg·m−2 | 21.07±3.99 | 20.38±3.59 | 20.80±3.84 |
| Females | 71 (40.1) | 61 (51.7) | 132 (44.7) |
| FEV1 L | 2.07±0.82## | 1.95±0.69 | 2.02±0.77¶¶ |
| FEV1 % pred | 62.4±16.45## | 61.4±16.13 | 62.0±16.30¶¶ |
| Microbiology | |||
| Pseudomonas aeruginosa | |||
| Mucoid | 58 (32.8) | 48 (40.7) | 106 (35.9) |
| Nonmucoid | 42 (23.7) | 32 (27.1) | 74 (25.1) |
| Staphylococcus aureus | 32 (18.1) | 25 (21.2) | 57 (19.3) |
| Aspergillus spp. | 28 (15.8) | 11 (9.3) | 39 (13.2) |
| Chronic antibiotic use >10% at baseline | |||
| Azithromycin | 98 (55.4) | 60 (50.8) | 158 (53.6) |
| Colistin# | 73 (41.2) | 45 (38.1) | 118 (40.0) |
| Tobramycin# | 43 (24.3) | 35 (29.7) | 78 (26.4) |
| Flucloxacillin | 5 (25.4) | 23 (19.5) | 68 (23.1) |
| Drugs for obstructive airway diseases | 148 (83.6) | 101 (85.6) | 249 (84.4) |
| ICS¶ | 103 (58.2) | 73 (61.9) | 176 (59.7) |
| SABA+ | 137 (77.4) | 96 (81.4) | 233 (79.0) |
| LABA§ | 98 (55.4) | 64 (54.2) | 162 (54.9) |
| Otherƒ | 38 (21.5) | 21 (17.8) | 59 (20.7) |
| rhDNase users | 96 (54.2) | 67 (56.8) | 163 (55.3) |
| FEV1 L | 1.96±0.78++ | 1.87±0.64 | 1.92±0.72 |
| FEV1 % pred | 59.2±17.26++ | 57.9±16.38 | 58.7±16.86 |
| rhDNase nonusers | 81 (45.8) | 51 (43.2) | 132 (44.7) |
| FEV1 L | 2.20±0.85 | 2.06±0.75 | 2.14±0.81 |
| FEV1 % pred | 66.2±14.68 | 66.1±14.69 | 66.1±14.63 |
Data are presented as n, mean±sd or n (%). BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted; ICS: inhaled corticosteroid; SABA: short-acting β-agonist; LABA: long-acting β-agonist; rhDNase: recombinant human deoxyribonuclease. #: 98.3% of colistin and 92.3% of tobramycin was nebulised at baseline; ¶: including combinations and single agents; +: salbutamol and terbutaline; §: salmeterol, formoterol or combinations; ƒ: including leukotriene receptor antagonists, anticholinergic bronchodilators, theophylline, aminophylline and nedocromil; ##: n=176; ¶¶: n=294; ++: n=95.